Results 81 to 90 of about 24,911 (203)

Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. [PDF]

, 2015
BackgroundDemethylation process is necessary for the expression of various factors involved in chemotherapy cytotoxicity or resistance. Platinum-resistant cells may have reduced expression of the copper/platinum transporter CTR1.
Culotta, Kirk, Falchook, Gerald, Fu, Siqing, He, Guangan, Hess, Kenneth, Issa, Jean-Pierre J, Jelinek, Jaroslav, Kurzrock, Razelle, Naing, Aung, Piha-Paul, Sarina, Said, Rabih, Siddik, Zahid H, Stewart, David J, Tsimberidou, Apostolia M, Wistuba, Ignacio, Zinner, Ralph   +15 more
core   +2 more sources

GNL3 Orchestrates AR Transcriptional Programs to Drive Castration‐Resistant Prostate Cancer and Immune Evasion

Advanced Science, Volume 13, Issue 26, 8 May 2026.
GNL3 is a novel AR coregulator with dual coactivator and corepressor functions in prostate cancer (PCa). Our study uncovers a previously unrecognized mechanism by which the AR transcriptional complex integrates oncogenic signaling and immune suppression.
Cuiting Zhang, Tin Long Cheong, Nitin Narwade, Dandan Dong, Mokan Deng, Zhengqiang Miao, Zhaoqiang Ding, Wenchao Li, Kate Man Kei Lei, Gong‐Hong Wei, Terence Chuen Wai Poon, Chu‐Xia Deng, Edwin Cheung   +12 more
wiley   +1 more source

Combination Therapies of Guadecitabine and Immune Checkpoint Inhibitors in a Murine Triple-Negative Breast Cancer Model [PDF]

, 2020
Combination Therapies of Guadecitabine and Immune Checkpoint Inhibitors in a Murine Triple-Negative Breast Cancer Model Jamie-Jean Gilmer, Depts. of Biology and Chemistry, with Dr. Sarah Golding, Dept.
Gilmer, Jamie-Jean
core   +1 more source

A semantic web framework to integrate cancer omics data with biological knowledge [PDF]

, 2012
BACKGROUND: The RDF triple provides a simple linguistic means of describing limitless types of information. Triples can be flexibly combined into a unified data source we call a semantic model.
James P McCusker, Kei-Hoi Cheung, Matthew E Holford, Michael Krauthammer   +3 more
core   +1 more source

Emerging Roles of Adenosine Metabolism in Astrocytes During Brain Injury

CNS Neuroscience &Therapeutics, Volume 32, Issue 5, May 2026.
Adenosine, as a key metabolic and neurotransmitter in the brain, has become an important therapeutic target for improving the efficacy of immunotherapy for stroke. However, gaps in knowledge about its metabolic pathways have become a key factor limiting its clinical translation.
Shu Zhu, Shanshan Zhong, Xiaoru Lin, Chuansheng Zhao, Yugang Li   +4 more
wiley   +1 more source

Guillain–Barre Syndrome With Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation

The Kaohsiung Journal of Medical Sciences, EarlyView.
Chin‐Mu Hsu, Ping‐Hsuan Lin, Chia‐Hsuan Chiu, Hui‐Hua Hsiao   +3 more
wiley   +1 more source

Targeting the nuclear export receptor exportin‐1 in acute myeloid leukaemia: From biology to clinical translation

Clinical and Translational Medicine, Volume 16, Issue 5, May 2026.
• XPO1 hyperactivation promotes leukaemogenesis by altering nucleocytoplasmic transport and transcriptional control in acute myeloid leukaemia (AML). • Selinexor and eltanexor show preferential activity in NPM1‐mutated, DEK::NUP214‐positive and SF3B1‐mutated myeloid neoplasms.
Yifan Liu, Xiaoya Yun, Weidong Ding, Suxiao Li, Hui Liu   +4 more
wiley   +1 more source

The type of DNA damage response after decitabine treatment depends on the level of DNMT activity

Life Science Alliance
Chromatin-centred proteomics study in stem cells with different DNMT expression levels and activities reveals that decitabine invokes different DNA damage responses depending on the amount of the induced DNA-DNMT crosslinks.
Tina Aumer, Maike Däther, Linda Bergmayr, Stephanie Kartika, Theodor Zeng, Qingyi Ge, Grazia Giorgio, Alexander J Hess, Stylianos Michalakis, Franziska R Traube   +9 more
doaj   +1 more source

Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report

Journal of Immunology Research, 2014
Aberrant DNA methylation is one of the main drivers of tumor initiation and progression. The reversibility of methylation modulation makes it an attractive target for novel anticancer therapies.
Hui Fan, Xuechun Lu, Xiaohui Wang, Yang Liu, Bo Guo, Yan Zhang, Wenying Zhang, Jing Nie, Kaichao Feng, Meixia Chen, Yajing Zhang, Yao Wang, Fengxia Shi, Xiaobing Fu, Hongli Zhu, Weidong Han   +15 more
doaj   +1 more source

Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia

Hematological Oncology, Volume 44, Issue 3, May 2026.
ABSTRACT The optimal duration of hypomethylating agent (HMA) therapy combined with venetoclax (Ven) in newly diagnosed acute myeloid leukemia (ND‐AML) remains uncertain. Standard of care (SOC) uses 5‐day decitabine (Dec‐5) or 7‐day azacitidine (Aza‐7), while extended HMA regimens (e.g., 10‐day decitabine [Dec‐10] during cycle 1) have also been explored,
Georgio Medawar, Jean‐Sebastien Anoma, Elizabeth Hill, Serena Tharakan, Dahniel L. Sastow, Vincent Lok, Su Bin Hahn, Sarah Chen, Thomas Kehoe, Chidambaram Ramasamy, Julian Guetta‐Weiss, Kapil Meleveedu, Chenyu Lin, David M. Swoboda, Douglas Tremblay, Alexander Coltoff   +15 more
wiley   +1 more source